Anybody know any more about the FDA rejecting the drug Olumiant aka Baracitinib? Eli Lilly had partnered with a company called Incyte and it was supposed to be in the same class as Xeljanz. I think they said it was a JAK inhibitor. Do you know who is doing trials or why it was rejected specifically? Have they put it on the backburner or are they still going forward with it?